The Gaucher earlier diagnosis consensus point-scoring system (GED-C PSS): Evaluation of a prototype in Finnish Gaucher disease patients and feasibility of screening retrospective electronic health record data for the recognition of potential undiagnosed patients in Finland

Markku J Savolainen; Antti Karlsson; Samppa Rohkimainen; Iiro Toppila; Mariann I Lassenius; Carlos Vaca Falconi; Kristiina Uusi-Rauva; Kaisa Elomaa

doi:10.1016/j.ymgmr.2021.100725

The Gaucher earlier diagnosis consensus point-scoring system (GED-C PSS): Evaluation of a prototype in Finnish Gaucher disease patients and feasibility of screening retrospective electronic health record data for the recognition of potential undiagnosed patients in Finland

Mol Genet Metab Rep. 2021 Feb 9:27:100725. doi: 10.1016/j.ymgmr.2021.100725. eCollection 2021 Jun.

Authors

Markku J Savolainen¹, Antti Karlsson², Samppa Rohkimainen³, Iiro Toppila⁴, Mariann I Lassenius⁴, Carlos Vaca Falconi⁵, Kristiina Uusi-Rauva⁴, Kaisa Elomaa⁶

Affiliations

¹ Oulu University Hospital, PO Box 10, 90029 OYS, Oulu, Finland.
² Auria Biobank, Turku University Hospital, University of Turku, PO Box 52, 20521 Turku, Finland.
³ Biobank Borealis of Northern Finland, PO Box 50, 90029 OYS, Oulu, Finland.
⁴ Medaffcon Oy, Tietäjäntie 2, 02130 Espoo, Finland.
⁵ Takeda Pharma AB, Vasagatan 7, 11120 Stockholm, Sweden.
⁶ Takeda Oy, Ilmalantori 1, 00101 Helsinki, Finland.

Abstract

Background: Gaucher disease (GD) is a rare inherited multiorgan disorder, yet a diagnosis can be significantly delayed due to a broad spectrum of symptoms and lack of disease awareness. Recently, the prototype of a GD point-scoring system (PSS) was established by the Gaucher Earlier Diagnosis Consensus (GED-C) initiative, and more recently, validated in Gaucher patients in UK. In our study, the original GED-C PSS was tested in Finnish GD patients. Furthermore, the feasibility of point scoring large electronic health record (EHR) data set by data mining to identify potential undiagnosed GD cases was evaluated.

Methods: This biobank study was conducted in collaboration with two Finnish biobanks. Five previously diagnosed Finnish GD patients and ~ 170,000 adult biobank subjects were included in the study. The original PSS was locally adjusted due to data availability issues and applied to the Finnish EHR data representing special health care recordings.

Results: All GD patients had high levels of the biomarker lyso-Gb1 and deleterious GBA mutations. One patient was a compound heterozygote with a novel variant, potentially pathogenic mutation. Finnish EHR data allowed the retrospective assessment of 27-30 of the 32 original GED-C signs/co-variables. Total point scores of GD patients were high but variable, 6-18.5 points per patient (based on the available data on 28-29 signs/co-variables per patient). All GD patients had been recorded with anaemia while only three patients had a record of splenomegaly. 0.72% of biobank subjects were assigned at least 6 points but none of these potential "GD suspects" had a point score as high as 18.5. Splenomegaly had been recorded for 0.25% of biobank subjects and was associated with variable point score distribution and co-occurring ICD-10 diagnoses.

Discussion: This study provides an indicative GED-C PSS score range for confirmed GD patients, also representing potential mild cases, and demonstrates the feasibility of scoring Finnish EHR data by data mining in order to screen for undiagnosed GD patients. Further prioritisation of the "GD suspects" with more developed algorithms and data-mining approaches is needed.

Funding: This study was funded by Shire (now part of Takeda).

Keywords: Biobank study; DBS, dried blood spot; EHR, Electronic health record; Electronic health record; GBA; GBA1/GBA, β-glucocerebrosidase gene; GD, Gaucher disease; GED-C, The Gaucher Earlier Diagnosis Consensus; Gaucher disease; Gaucher earlier diagnosis consensus point-scoring system; GlcCer, β-glucosylceramide; GlcCerase, β-glucosylceramidase; GlcSph/Lyso-Gb1, β-glucosylsphingosine; HDSF, Hospital District of Southwest Finland; Lyso-Gb1; NOHD, Northern Ostrobothnia Hospital District; PSS, Point-scoring system.